Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™(eflapegrastim-xnst) Injection

Date:
Oct 24, 2022

Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™(eflapegrastim-xnst) Injection

Distribution partners stocked with product and ready to sell into estimated $2 billion market


Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or the “Company”), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the commercial availability of ROLVEDON™ (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. ROLVEDON received U.S. Food and Drug Administration approval in September 2022.


“We are thrilled to launch ROLVEDON into an estimated $2 billion market. Our distribution partners have stocked the product and we are ready to take advantage of this compelling market opportunity,” said Tom Riga, President and Chief Executive Officer of Spectrum Pharmaceuticals. “This is an important milestone in Spectrum’s transition to a commercial stage company, and we are excited to deliver ROLVEDON to the patients who need it.”